Product Information
ERY-TAB DR 333 MG TABLET is a generic product labeled by Arbor Pharmaceuticals, Inc., priced at $3.2578 per EA under NDC 24338012403. Its NADAC has been published 179 times since Feb 7, 2018.
FDA first approved this application before 1982. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
333 mg/1
Manufacturer
Arbor Pharmaceuticals, Inc.NDC
24338012403
Classification
Generic
Dosage Form
TABLET, DELAYED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ERYTHROMYCINApproval Type
Generic (ANDA)
FDA Application
ANDA062298FDA Approved
Before 1982
TE Code
AB
On Market Since
4/18/2011
Pharmacological Classes
Price Statistics
The NADAC for ERY-TAB DR 333 MG TABLET has been published 179 times since Feb 7, 2018, and over the history we have for it it has declined 61.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $3.2578 per EA |
|---|---|
| All-time high | $8.5150 (Jan 16, 2019) |
| All-time low | $2.5179 (Aug 21, 2024) |
| 52-week high | $3.7275 |
| 52-week low | $3.2578 |
| Median price | $3.6029 |
| Average price | $4.8308 |
| Largest weekly change | -60.1% (Apr 17, 2024) |
| Weeks tracked | 179 |
| Tracking since | Feb 7, 2018 |
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Arbor Pharmaceuticals, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Erythromycin market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Macrolide Antimicrobial class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ERY-TAB DR 333 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for ERY-TAB DR 333 MG TABLET, manufactured by Arbor Pharmaceuticals, Inc., is $3.2578 per EA (NDC 24338012403), effective Sep 30, 2026.
How has the price of ERY-TAB DR 333 MG TABLET changed over time?
Over the history we have for it, the NADAC for ERY-TAB DR 333 MG TABLET has declined 61.7%. It has been tracked across 179 weekly CMS publications since Feb 7, 2018.
What are the highest and lowest recorded NADAC prices for ERY-TAB DR 333 MG TABLET?
Since Feb 7, 2018, the NADAC for ERY-TAB DR 333 MG TABLET has ranged from a low of $2.5179 (Aug 21, 2024) to a high of $8.5150 (Jan 16, 2019), with a median of $3.6029 per EA.
Are there cheaper alternatives to ERY-TAB DR 333 MG TABLET?
3 manufacturers publish a NADAC-priced product with the same active ingredient and strength as ERY-TAB DR 333 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures ERY-TAB DR 333 MG TABLET?
ERY-TAB DR 333 MG TABLET (NDC 24338012403) is labeled by Arbor Pharmaceuticals, Inc., and CMS classifies it as a generic product.